Back to Search
Start Over
Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance.
- Source :
-
BMJ case reports [BMJ Case Rep] 2016 Jun 17; Vol. 2016. Date of Electronic Publication: 2016 Jun 17. - Publication Year :
- 2016
-
Abstract
- We report a case of a 60-year-old man who was referred to a palliative care clinic with monoclonal gammopathy of undetermined significance (MGUS)-associated neuropathy, responding to a therapeutic trial of warfarin. Electromyography showed distal symmetric sensory axonal neuropathy. The patient reported having had improvement of his neuropathic symptoms while taking warfarin postoperatively for thromboprophylaxis 1 year prior, and recurrence of his symptoms after the warfarin was discontinued. The patient was rechallenged with a trial of warfarin, targeting an international normalised ratio of 1.5-2.0. His pain scores decreased from 5/10 to 3/10 at 1 month and symptom improvement was maintained through 24 months of follow-up. Warfarin had a remarkable impact on our patient's symptoms and quality of life. The mechanisms mediating the symptomatic benefit with warfarin are unclear; however, a placebo effect is unlikely. Further studies may help guide the use of warfarin for MGUS-associated neuropathy.<br /> (2016 BMJ Publishing Group Ltd.)
Details
- Language :
- English
- ISSN :
- 1757-790X
- Volume :
- 2016
- Database :
- MEDLINE
- Journal :
- BMJ case reports
- Publication Type :
- Academic Journal
- Accession number :
- 27317760
- Full Text :
- https://doi.org/10.1136/bcr-2016-215518